27 juillet 2020 | 39:23
The Supreme Court's Regeneron Pharmaceuticals Inc v Kymab Ltd decision to revoke two patents for transgenic mouse technology has caused concern to biotech patent owners, especially since the Supreme Court expressed a need to rebalance patent law.
Has this case shifted the boundaries of patent protection, or merely clarified the status quo? What is its context, and broader impact on patents both within and outside the life sciences technology area?
Our experts explain the case and answer these questions in this webinar.